Study investigates the occurrence of ADAMTS13 antibodies in COVID-19 patients and their association with disease severity and lower ADAMTS13 activity. The findings suggest the need to include ADAMTS13 antibodies in diagnosing and managing SARS-CoV-2 infections.
Nura Bio secures funding to advance neuroprotective therapies
The company’s lead asset demonstrated neuroprotection in preclinical models of nerve injury and disease. Credit: Jo Panuwat D/Shutterstock. Nura Bio has secured an additional $68m
September 18, 2024